Thank you for your interest in volunteering for one of the University of Southern California Alzheimer’s Therapeutic Research Institute (USC ATRI) coordinated studies.
To participate, please find a trial that is right for you (or someone you love) and contact a clinical site near you. Each of our studies have different eligibility criteria. While not everyone can join a trial, you can always become an advocate by sharing the trials with someone you know who might be able to participate.
To watch an informational video about why your participation in clinical trials is so important, click here.
We appreciate your support as we seek to prevent and treat Alzheimer’s disease.
Active Studies – Recruiting
If you are 50 years of age or older, you can monitor your own cognitive health by participating in the Alzheimer Prevention Trials (APT) Webstudy. The APT Webstudy is designed to identify people who may have an increased risk for developing Alzheimer’s disease, using the latest technology to monitor their cognitive performance through regular online memory testing. Volunteers of the APT Webstudy participate at their convenience, anywhere they have access to the internet. APT Webstudy participants benefit by:
- Having their cognitive health assessed over time;
- Being on the ‘fast track’ for relevant clinical trials to prevent Alzheimer’s;
- Making an invaluable contribution to advancing Alzheimer’s research, perhaps helping those in the research field find the first Alzheimer’s survivor; and
- Helping ensure that future generations do not experience Alzheimer’s and its difficult challenges.
The APT Webstudy is being conducted by the University of Southern California Alzheimer’s Therapeutic Research Institute (USC ATRI), funded by the National Institute on Aging (NIA), and is non-interventional.
To participate in the APT Webstudy or to learn more, please visit www.aptwebstudy.org. Those identified from the APT Webstudy to have a potential increased risk for memory loss will be referred to participating TRC-PAD (below) site locations. You do not have to participate in the TRC-PAD in-person study to participate in the online APT Webstudy. Participants have the option of participating in either English or Spanish.
The LEADS study – or the Longitudinal Early-Onset Alzheimer’s Disease Study (LEADS) explores the development of early-onset Alzheimer’s disease and how it compares to the more common late-onset Alzheimer’s disease. Better understanding of this form of the disease may ultimately lead to more effective treatments. LEADS is a 2-year observational study designed to enroll 500 participants. Researchers are also recruiting cognitively normal volunteers for a 1-year comparison.
The purpose of the Memory Improvement Through Nicotine Dosing (MIND) study is to determine whether daily transdermal nicotine (patch) will have a positive effect on early memory impairment in participants diagnosed with Mild Cognitive Impairment (MCI). We are looking for healthy, non-smoking adults, age 55+.
Those identified to have a potential increased risk for memory loss caused by Alzheimer’s disease, will be referred from the APT Webstudy (above) to the Trial Ready Cohort for the Prevention of Alzheimer’s Dementia (TRC-PAD) in-person study. The purpose of TRC-PAD is to find as many people as possible (also called a “cohort”) who are interested in participating in clinical trials aimed at discovering treatments that will reduce the risk of developing Alzheimer’s dementia. TRC-PAD will help researchers enroll participants into these trials quickly to allow new treatments to be discovered as soon as possible. Participants do not have to participate in the TRC-PAD study in order to participate in the online APT Webstudy.
TRC-PAD is being conducted by the University of Southern California Alzheimer’s Therapeutic Research Institute (USC ATRI), funded by the National Institute on Aging (NIA), and is non-interventional.
To get involved with the TRC-PAD in-person study, please register and participate in the APT Webstudy first at www.aptwebstudy.org. Those identified from the APT Webstudy to have a potential increased risk for memory loss will be referred to participating TRC-PAD site locations.
Active Studies – Not Recruiting
For more information, click here.
“We call the condition of memory impairment alone amnestic Mild Cognitive Impairment (aMCI),” says Dr. Ronald Petersen, director of the NIA-funded Mayo Alzheimer’s Disease Research Center. “Researchers are particularly interested in the brain changes and memory loss of aMCI, because more people with this condition go on to develop AD than do people without it. We don’t yet know for sure whether aMCI is a separate condition or a transitional stage between normal aging and AD.”
The Early Trial
Elevations of liver enzymes, which were serious in nature, were observed in some study participants who received the Janssen BACE inhibitor, atabecestat. After a thorough evaluation of all available liver safety data from their studies, Janssen concluded that the benefit-risk ratio was no longer favorable to continue development of atabecestat for people who have late-onset preclinical stage Alzheimer’s disease.